Integrating Bispecific Antibodies Into Frontline Therapy for Newly Diagnosed Multiple Myeloma

Dr. Hans Lee and Dr. Muhamed Baljevic discuss the emerging role of bispecific antibodies in frontline treatment for newly diagnosed multiple myeloma, focusing on data from the MajesTEC-5 study and other ongoing investigations. Dr. Baljevic highlights the depth of response observed with teclistamab-containing induction regimens, including high rates of stringent complete response and MRD negativity, and discusses the potential for these approaches to further improve outcomes beyond established quadruplet regimens. The panel considers whether the available evidence is sufficient to support broader incorporation of bispecific antibodies into frontline practice, while acknowledging that additional data are needed. Dr. Baljevic also discusses ongoing studies evaluating bispecific antibodies for MRD-positive patients and as consolidation therapy. The experts address practical considerations for safely delivering these therapies, including infection risk, CRS management, monitoring, follow-up, and logistical requirements. Finally, they emphasize the importance of developing strategies to safely implement these highly effective approaches in community settings and expanding equitable access to patients who may benefit from them.